ANTX
AN2 Therapeutics, Inc.
$4.50
-0.13 (-2.81%)
At close · Jul 10
Market Cap
$162.07M
Shares
36,016,161
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.50
Open$4.62
Day$4.28–4.68
52W$1.00–6.91
Avg vol 30d365K
Short int1.9M · 5.3% float · 2.9d
Short vol86%
Last earningsMay 19, 2026
DataMar 2022–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+78%
above
Price vs 50-day avg
−2%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
59%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+260%
trailing
YTD return
+295%
this year
Relative strength
+251%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+41% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$26.0K over 90 days · 100% sells
Short interest
Rising
5.34% of float · ▲ +47.3% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
52 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
EPS growth
+33%
Y/Y
Balance sheet
$19.9M
net cash
Quant / Vol
risk profile
Volatility
131%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+78%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
59%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+41% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$26.0K over 90 days · 100% sells
Short interest
Rising
5.34% of float · ▲ +47.3% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
52 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $5 · 59%
52-wk high $7
vs 200-day avg +78%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANTX
this stock
AN2 Therapeutics, Inc.
|
$162.07M | +294.7% | — | — | 5.3% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANTX | +1.8% | +9.8% | +260.0% | -7.0% | +294.7% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +0.4% | +5.7% | +250.9% | -8.1% | +284.0% |